Education
About Us
Working with TipRanks
Follow Us
Cellectis SA (CLLS)
NASDAQ:CLLS
CLLS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.10 - $3.10
Previous CloseN/A
Volume129.50K
Average Volume (3M)206.26K
Market Cap
$189.99M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta3.37
Next Earnings
Aug 04, 2025EPS Estimate
-0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.18
Shares Outstanding72,093,636
10 Day Avg. Volume366,431
30 Day Avg. Volume206,258
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.00
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.50Price Target Upside39.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Financial PositionManagement anticipates that the cash position is strong, with approximately $246 million in cash, cash equivalents, restricted cash, and fixed-term deposits.
Operational ProgressStrong demand for trial entry should facilitate enrollment speed for UCART20x22.
Strategic PartnershipsCellectis is making substantial progress across its clinical programs following a pipeline overhaul and strategic investment by AstraZeneca.
Bears Say
Data RequirementsDurability data in larger cohorts is needed to have confidence in the assets.
Financial PerformanceNet loss per share was ($0.18) versus consensus of ($0.15).
Cellectis SA News
CLLS FAQ
What was Cellectis SA’s price range in the past 12 months?
Cellectis SA lowest stock price was $1.10 and its highest was $3.10 in the past 12 months.
What is Cellectis SA’s market cap?
Cellectis SA’s market cap is $189.99M.
When is Cellectis SA’s upcoming earnings report date?
Cellectis SA’s upcoming earnings report date is Aug 04, 2025 which is in 2 days.
How were Cellectis SA’s earnings last quarter?
Cellectis SA released its earnings results on May 12, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.154 by -$0.026.
Is Cellectis SA overvalued?
According to Wall Street analysts Cellectis SA’s price is currently Undervalued.
Does Cellectis SA pay dividends?
Cellectis SA does not currently pay dividends.
What is Cellectis SA’s EPS estimate?
Cellectis SA’s EPS estimate is -0.21.
How many shares outstanding does Cellectis SA have?
Cellectis SA has 72,093,636 shares outstanding.
What happened to Cellectis SA’s price movement after its last earnings report?
Cellectis SA reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.154. Following the earnings report the stock price went down -6.623%.
Which hedge fund is a major shareholder of Cellectis SA?
Among the largest hedge funds holding Cellectis SA’s share is Bpifrance SA. It holds Cellectis SA’s shares valued at 0.
Cellectis SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.50 (39.44% Upside)
$3.50 (39.44% Upside)
Blogger Sentiment
Bullish
CLLS Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 1.5%
Last 30 Days ▼ 1.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
12.10%
12-Months-Change
Fundamentals
Return on Equity
-58.55%
Trailing 12-Months
Asset Growth
2.72%
Trailing 12-Months
Company Description
Cellectis SA
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
CLLS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a positive outlook for Cellectis, highlighted by strategic collaborations, strong financial positioning, and advancements in clinical trials. Challenges include ongoing arbitration with Servier and patient enrollment progress, but these are outweighed by the company's achievements.Read More>CLLS Stock 12 Month Forecast
Average Price Target
$3.50
▲(39.44%Upside)
Technical Analysis
Editas Medicine
―
Nkarta
―
4D Molecular Therapeutics
―
Vor Biopharma
―
Caribou Biosciences
―
Ownership Overview
―
Insiders
0.66% Mutual Funds
11.88% Other Institutional Investors
87.46% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---